Faeth Therapeutics, Inc. Insider Trading
SNSE
Insiders bought $1.19M on the open market and sold nothing.
Get an email when SNSE's executives or directors buy, or make a large sale outside a plan.
Trades · last 2 years
| Date | Insider | Trade | Shares | Price | Value | Of their stake | Filing |
|---|---|---|---|---|---|---|---|
| Jun 29 – Jul 1 | Brian C Stephenson Chief Financial Officer | Bought 6 parts | 13,634 | $23.92 average | 326K | 41% | Form 4 |
| Jun 24 – 26 | Brian C Stephenson Chief Financial Officer | Bought 8 parts | 15,641 | $25.65 average | 401K | 90% | Form 4 |
| Jun 22 – 23 | Brian C Stephenson Chief Financial Officer | Bought 8 parts | 17,413 | $23.31 average | 406K | New | Form 4 |
| Jun 22 | Anand Kiran Parikh President and CEO | Bought | 2,806 | $19.76 | 55K | 0.3% | Form 4 |
| Jun 1 | Cambrian Biopharma Inc Large holder | SoldNo plan 2 parts | 25,000 | $20.02 average | 501K | 16% | Form 4 |
| Jun 1 | James Peyer Large holder | SoldNo plan 2 parts | 25,000 | $20.02 average | 501K | 16% | Form 4 |
| Apr 2 – 7 | ICS Opportunities II LLC Large holder | SoldNo plan 12 parts | 17,076 | $31.51 average | 538K | 11% | Form 4 |
| Apr 2 – 7 | ICS Opportunities II LLC Large holder | Bought 5 parts | 4,215 | $33.54 average | 141K | 3.2% | Form 4 |
| Mar 31 – Apr 1 | Millennium Management LLC Large holder | SoldNo plan 7 parts | 2,741 | $28.07 average | 77K | 1.8% | Form 4 |
| Mar 31 – Apr 1 | Millennium Management LLC Large holder | Bought 10 parts | 12,180 | $31.37 average | 382K | 9.0% | Form 4 |
| Mar 26 – 30 | ICS Opportunities II LLC Large holder | SoldNo plan 6 parts | 3,250 | $27.51 average | 89K | 2.2% | Form 4 |
| Mar 26 – 30 | ICS Opportunities II LLC Large holder | Bought 11 parts | 30,585 | $26.75 average | 818K | 27% | Form 4 |
| Dec 9, 2025 | Cambrian Biopharma Inc Large holder | SoldNo plan 4 parts | 6,612 | $8.25 average | 55K | 4.1% | Form 4 |
| Dec 8, 2025 – Dec 9, 2025 | James Peyer Large holder | SoldNo plan 4 parts | 6,612 | $8.25 average | 55K | 4.1% | Form 4 |
| Dec 4, 2025 – Dec 5, 2025 | Cambrian Biopharma Inc Large holder | SoldNo plan 4 parts | 21,295 | $10.93 average | 233K | 12% | Form 4 |
| Dec 4, 2025 – Dec 5, 2025 | James Peyer Large holder | SoldNo plan 4 parts | 21,295 | $10.93 average | 233K | 12% | Form 4 |
- Jun 29 – Jul 1Brian C StephensonChief Financial Officer · bought 13,634 at avg $23.92326K41% of stake
- Jun 24 – 26Brian C StephensonChief Financial Officer · bought 15,641 at avg $25.65401K90% of stake
- Jun 22 – 23Brian C StephensonChief Financial Officer · bought 17,413 at avg $23.31406KNew position
- Jun 22Anand Kiran ParikhPresident and CEO · bought 2,806 at $19.7655K0.3% of stake
- Jun 1No planCambrian Biopharma IncLarge holder · sold 25,000 at avg $20.02501K16% of stake
- Jun 1No planJames PeyerLarge holder · sold 25,000 at avg $20.02501K16% of stake
- Apr 2 – 7No planICS Opportunities II LLCLarge holder · sold 17,076 at avg $31.51538K11% of stake
- Apr 2 – 7ICS Opportunities II LLCLarge holder · bought 4,215 at avg $33.54141K3.2% of stake
- Mar 31 – Apr 1No planMillennium Management LLCLarge holder · sold 2,741 at avg $28.0777K1.8% of stake
- Mar 31 – Apr 1Millennium Management LLCLarge holder · bought 12,180 at avg $31.37382K9.0% of stake
- Mar 26 – 30No planICS Opportunities II LLCLarge holder · sold 3,250 at avg $27.5189K2.2% of stake
- Mar 26 – 30ICS Opportunities II LLCLarge holder · bought 30,585 at avg $26.75818K27% of stake
- Dec 9, 2025No planCambrian Biopharma IncLarge holder · sold 6,612 at avg $8.2555K4.1% of stake
- Dec 8, 2025 – Dec 9, 2025No planJames PeyerLarge holder · sold 6,612 at avg $8.2555K4.1% of stake
- Dec 4, 2025 – Dec 5, 2025No planCambrian Biopharma IncLarge holder · sold 21,295 at avg $10.93233K12% of stake
- Dec 4, 2025 – Dec 5, 2025No planJames PeyerLarge holder · sold 21,295 at avg $10.93233K12% of stake
Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.
Peers
Pharmaceutical Preparations · Pick stocks to compare with SNSE
Held by ETFs
SNSE is in 2 US ETFs. The largest of them, with SNSE's weight in each:
Spot a number that looks wrong? Check it in SNSE's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing SNSE
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.